- Home
- UMC vs RPRX Comparison
UMC vs RPRX Comparison
Compare UMC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMC
- RPRX
- Stock Information
- Founded
- UMC 1980
- RPRX 1996
- Country
- UMC Taiwan
- RPRX United States
- Employees
- UMC N/A
- RPRX N/A
- Industry
- UMC Semiconductors
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- UMC Technology
- RPRX Health Care
- Exchange
- UMC Nasdaq
- RPRX Nasdaq
- Market Cap
- UMC 18.8B
- RPRX 15.6B
- IPO Year
- UMC 2000
- RPRX 2020
- Fundamental
- Price
- UMC $6.59
- RPRX $35.87
- Analyst Decision
- UMC Sell
- RPRX Strong Buy
- Analyst Count
- UMC 4
- RPRX 3
- Target Price
- UMC $7.40
- RPRX $45.33
- AVG Volume (30 Days)
- UMC 6.3M
- RPRX 3.1M
- Earning Date
- UMC 10-29-2025
- RPRX 08-06-2025
- Dividend Yield
- UMC 5.65%
- RPRX 2.45%
- EPS Growth
- UMC N/A
- RPRX 54.86
- EPS
- UMC 0.11
- RPRX 2.32
- Revenue
- UMC $8,120,907,266.00
- RPRX $2,305,243,000.00
- Revenue This Year
- UMC $3.78
- RPRX $33.77
- Revenue Next Year
- UMC $5.40
- RPRX $4.62
- P/E Ratio
- UMC $12.29
- RPRX $15.45
- Revenue Growth
- UMC 6.28
- RPRX 3.02
- 52 Week Low
- UMC $5.61
- RPRX $24.05
- 52 Week High
- UMC $8.86
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- UMC 32.14
- RPRX 42.45
- Support Level
- UMC $6.64
- RPRX $35.48
- Resistance Level
- UMC $6.80
- RPRX $36.99
- Average True Range (ATR)
- UMC 0.12
- RPRX 0.68
- MACD
- UMC 0.01
- RPRX -0.14
- Stochastic Oscillator
- UMC 0.76
- RPRX 7.28
About UMC United Microelectronics Corporation (NEW)
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the us, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.